Overview A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease Status: Completed Trial end date: 2010-11-01 Target enrollment: Participant gender: Summary This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease. Phase: Phase 3 Details Lead Sponsor: IMPAX Laboratories, Inc.Impax Laboratories, LLCTreatments: CarbidopaCarbidopa, levodopa drug combinationLevodopa